Swedish Study of Immunotherapy for Milk Allergy in Children (SWITCH)

This trial is a two-armed open randomized controlled trial in children aged 5-15 years with challenge proven Immunoglobulin E (IgE)-associated milk allergy.The purpose is to determine if oral immunotherapy with milk can induce tolerance to milk. The active intervention is intake of increasing amounts of fresh milk for six months followed by three years of maintenance treatment with milk. The control group continues their elimination (milk free) diet. The trial will recruit patients at ten pediatric departments in Sweden, coordinated by Umeå University. The primary outcome is milk tolerance (defined as a negative double-blind placebo-controlled milk challenge) at trial completion 3.5 years after start of treatment. Secondary outcomes include allergic symptoms during treatment documented as certain allergic manifestations, changes in immunological and microbial biomarkers, quality of life and nutritional status.

Study Overview

• Status: Recruiting
• Conditions: Milk Allergy
• Intervention / Treatment: Other: Milk protein in fresh milk

Detailed Description

The underlying hypothesis is that exposure to milk in a controlled way can be delivered safely and induce tolerance to milk.The aim of this trial is to evaluate a specific protocol for oral milk intake to achieve sustainable tolerance.

Before randomization all patients are tested for milk allergy using a double-blind placebo-controlled milk challenge and baseline laboratory analyses (specific IgE). Patients with confirmed, challenge-proven milk allergy are randomized to oral immunotherapy (active group) or milk-free diet (control group).The active group will receive a stepwise increase in oral milk intake. The increased dose will be given in hospital outpatient clinics by experienced study staff following a standard protocol. All other doses are given att home where the patients have adrenaline ready to use. When the patient has reached a daily intake of 100 ml of milk without serious allergic reactions they will be maintained on this dosis for three years. At this stage (after finished dose escalation or after six months for the control group) the patients will be tested for the second set of laboratory analyses.

During maintenance, the patients in the active group are encouraged not to avoid milk protein and instead eat milk-containing food when it is offered. Patients in the control group receive standard care with exclusion of milk from their diet for the whole trial duration.

After three years of maintenance therapy for the active group, both groups avoid milk for one week and then undergo a double-blind placebo-controlled milk challenge and the third set of samples for immunological comparison.

The immunological markers are Immunoglobulins (E, G4, A), microbiota and basophilic activation. All patients are also evaluated for quality of life and nutritional status.

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Christina West, Associated professor; Phone Number: +46 703972792; Email: christina.west@umu.se
• Study Contact Backup: Name: Solveig Röisgård; Phone Number: +46 702791831; Email: solveig.roisgard@regionjh.se

Study Locations

• Sweden
  • Jämtland Härjedalen
    • Östersund, Jämtland Härjedalen, Sweden, 83183
      • Recruiting
      • Solveig Röisgård
      • Contact: Solveig Röisgård, MD; Phone Number: +46702791831; Email: solveig.roisgard@regionjh.se
      • Contact: Christina West, MD, PhD; Phone Number: +46703972792; Email: christina.west@umu.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 13 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Immunoglobulin E (IgE) milk >0.1 kU/L
• Allergic reaction within 2 hours after intake of milk protein
• Age 5-15 years

Exclusion Criteria:

• Uncontrolled asthma, >12 % increase in Forced Expiratory Volume in 1 second (FEV1) after inhaled bronchodilatator and Asthma Control Test (ACT)<20
• No allergic reaction at a controlled milk challenge
• Cancer
• Severe immune deficiency
• Autoimmune disease
• Chronic urticaria
• Eosinophil esophagitis
• Pregnancy and breastfeeding
• Ongoing immunotherapy to one or more allergens

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active immunotherapy with milk protein; Daily dose fresh milk protein increased in 11 steps	Other: Milk protein in fresh milk; Milk protein in increasing doses.
No Intervention: Control; Diet free from milk protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants that achieve tolerance to milk	Tolerance is defined as absence of IgE-mediated allergic symptoms connected to a double-blind placebo-controlled milk challenge	3.5 years after start of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in level of basophil activation (CD sens) in blood	Level of basophil activation at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins	At baseline, after 6 months, after 3.5 years
Changes in Quality Of Life: FAQLQ-PF	Quality Of Life, reported by questionnaire (FAQLQ-PF) after completion of the intervention (3.5 years) compared to pre-trial baseline level. The scale used is Emotional Impact, Food Related anxiety and Dietary Limitations. Each question of the FAQLQ is answered on a 7-point scale. Total FAQLQ scores and domain scores are calculated by dividing the sum of completed items by the number of completed items. Total FaQLQ and domain scores range from 1 "no impairment" to 7 "maximal impairment". Higher values are a worse outcome (low health related quality of life). Subscale is Health related quality of life (HRQoL summary score=(Emotional Impact subscale score + Food Related anxiety subscale score+Dietary Limitations subscale score)/3.	At baseline, after 3.5 years
Changes in nutritional status	Body Mass Index (BMI) after completion of the intervention (3.5 years) compared to pre-trial baseline levels	At baseline, after 3.5 years
Frequency of treatment-demanding adverse effects	Number of events with adrenaline injection within 2 hours after a dose of milk (one or two injections) during step-up and maintenance therapy respectively. Number of events with inhalation of bronchodilatator within 2 hours after a dose of milk during step up and maintenance therapy respectively. Number of participants with two or more events with adrenaline injections during step-up and maintenance respectively. Number of participants with two or more events with inhalation of bronchodilatator during step-up and maintenance therapy respectively. Number of participants with no events of adrenaline injections. Number of participants with no events of inhalation with bronchodilatator.	3.5 years
Changes in level of IgE milk in blood	Level of IgE milk including the components IgE casein, IgE lactoglobulin and lactalbumin at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins	Baseline, 6 months, 3.5 years
Changes in level of IgG4 milk in blood	Level of IgG4 milk at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins	Baseline, 6 months, 3.5 years
Changes in level of IgA in saliva	Level of IgA at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins	Baseline, 6 months, 3.5 years
Changes in overall microbial composition in stools	The overall microbial composition at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins will be assessed using amplicon sequencing	Baseline, 6 months, 3.5 years
Changes in overall microbial composition in saliva	The microbial composition at baseline, after dose escalation and after maintenance therapy and one additional week free from milk proteins will be assessed using amplicon sequencing	Baseline, 6 months, 3.5 years

Collaborators and Investigators

• Sponsor: Umeå University
• Investigators: Principal Investigator: Christina E West, MD,PhD, Umea University

Study record dates

Study Major Dates

• Study Start (Actual): April 20, 2018
• Primary Completion (Anticipated): October 20, 2024
• Study Completion (Anticipated): October 20, 2024

Study Registration Dates

• First Submitted: April 20, 2018
• First Submitted That Met QC Criteria: January 24, 2019
• First Posted (Actual): January 28, 2019

Study Record Updates

• Last Update Posted (Actual): May 20, 2020
• Last Update Submitted That Met QC Criteria: May 19, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Keywords: Microbiome; Quality of life; Basophil activation test; IgE; Cow milk allergy; Oral immune therapy
• Additional Relevant MeSH Terms: Immune System Diseases; Food Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Milk Hypersensitivity; Molecular Mechanisms of Pharmacological Action; Chelating Agents; Sequestering Agents; Caseins
• Other Study ID Numbers: F07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No